CYTK
Neutral signalScored 2026-10-24 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Cytokinetics, Incorporated
- Nom
- Cytokinetics, Incorporated
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.5B
- Employés
- 673
- PDG
- Robert I. Blum
- Site web
- https://www.cytokinetics.com
- Marché
- BCDABRVEKARDRNATNYA
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 24 500 titres (~1 660 140,00 $ US)
- Insiders
- Blum Robert ILandry Robert E
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$12,937,330
Avg sell (VWAP, 90d window) $70.34 vs last close $60.73 (-13.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$12,713,295 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-12
- Liquidity
- Liquid $116,466,090/day · 20d vol
- Last synced
-
2026-10-26 21:10:22
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-20 | Malik Fady Ibraham | Sell · S | 3,500 | $64.01 | $224,035 | Form 4 |
| 2026-10-12 | Blum Robert I | Sell · S · 10b5-1 | 7,500 | $62.88 | $471,600 | Form 4 |
| 2026-10-06 | Malik Fady Ibraham | Sell · S · 10b5-1 | 3,500 | $61.38 | $214,830 | Form 4 |
| 2026-09-28 | Blum Robert I | Sell · S · 10b5-1 | 7,500 | $65.46 | $490,950 | Form 4 |
| 2026-09-22 | Malik Fady Ibraham | Sell · S · 10b5-1 | 3,500 | $68.29 | $239,015 | Form 4 |
| 2026-09-15 | Blum Robert I | Sell · S · 10b5-1 | 97,926 | $69.33 | $6,789,210 | Form 4 |
| 2026-09-15 | Landry Robert E | Sell · S · 10b5-1 | 1,000 | $72.13 | $72,130 | Form 4 |
| 2026-09-14 | Blum Robert I | Sell · S · 10b5-1 | 7,500 | $73.44 | $550,800 | Form 4 |
| 2026-09-11 | Landry Robert E | Sell · S · 10b5-1 | 1,000 | $74.66 | $74,660 | Form 4 |
| 2026-09-08 | Malik Fady Ibraham | Sell · S · 10b5-1 | 3,500 | $75.46 | $264,110 | Form 4 |
| 2026-09-01 | PARSHALL B LYNNE | Sell · S · 10b5-1 | 5,000 | $71.48 | $357,400 | Form 4 |
| 2026-08-31 | Blum Robert I | Sell · S · 10b5-1 | 7,500 | $70.24 | $526,800 | Form 4 |
| 2026-08-31 | Callos Andrew | Sell · S · 10b5-1 | 10,000 | $70.24 | $702,400 | Form 4 |
| 2026-08-18 | Malik Fady Ibraham | Sell · S · 10b5-1 | 3,500 | $75.82 | $265,370 | Form 4 |
| 2026-08-10 | Blum Robert I | Sell · S · 10b5-1 | 7,500 | $76.76 | $575,700 | Form 4 |
| 2026-07-30 | Callos Andrew | Sell · S · 10b5-1 | 14,000 | $79.88 | $1,118,320 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-24 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
CYTK presents a moderate event-driven opportunity anchored by the anticipated Health Canada approval of aficamten and a Q3 earnings catalyst on Nov 4, but these are materially offset by severe balance sheet fragility —…
The first sentence of the analysis written for CYTK on 2026-10-24 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $12.7M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $12.7M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 4.53 · operating margin -695% — readings disagree
Suggested stop 58.79, nearest stored support minus 0.5 ATR(3.2% under the last close). Reward/risk to the next stored resistance is 0.39. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-22 Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK) Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Earnings and Valuation This table compares Actinium Pharmaceuticals and
- 2026-10-21 Cytokinetics to Announce Third Quarter Results on November 4, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics'' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.
- 2026-10-19 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.
- 2026-10-19 Can Myqorzo''s Expansion and Growing Adoption Drive CYTK''s Growth? Cytokinetics'' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
- 2026-10-19 Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
- 2026-10-14 Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative''s "150 MAIN STREET TRUST > BANK OF
- 2026-10-13 Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK) Maze Therapeutics (NASDAQ: MAZE - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Recommendations This is a breakdown of current ratings
- 2026-10-12 Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
- 2026-10-08 Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK) Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations. Risk and Volatility Cytokinetics has a beta of
- 2026-10-02 Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 88.5% | -1737.2% | -4284.1% | -154.6% | -127.1% | |
| Ebit Margin | -891.6% | -2722.8% | -6222.8% | -357.1% | -264.1% | |
| Ebitda Margin | -880.1% | -2671.2% | -6064.9% | -351.0% | -260.8% | |
| Operating Profit Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | |
| Pretax Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Continuous Operations Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Net Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Bottom Line Profit Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | |
| Current Ratio | 4.529 | 6.166 | 6.117 | 9.397 | 7.454 | |
| Quick Ratio | 4.529 | 6.166 | 6.117 | 9.397 | 7.454 | |
| Solvency Ratio | -0.372 | -0.377 | -0.425 | -0.341 | -0.357 | |
| Cash Ratio | 0.605 | 0.528 | 1.101 | 0.775 | 1.568 | |
| Price To Earnings Ratio | -9.716 | -8.943 | -15.319 | -10.582 | -16.279 | |
| Price To Earnings Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Forward Price To Earnings Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Price To Earnings Diluted Ratio | -9.716 | -8.943 | -15.319 | -10.582 | -16.279 | |
| Price To Earnings Diluted Growth Ratio | -0.399 | 2.565 | -0.592 | -0.194 | -0.386 | |
| Price To Book Ratio | -11.562 | -38.911 | -20.860 | -38.144 | 14.371 | |
| Price To Sales Ratio | 86.624 | 285.130 | 1,070.224 | 43.513 | 49.760 | |
| Price To Free Cash Flow Ratio | -14.260 | -13.175 | -19.384 | -13.240 | -18.310 | |
| Price To Operating Cash Flow Ratio | -14.953 | -13.305 | -19.450 | -13.741 | -24.589 | |
| Debt To Assets Ratio | 0.902 | 0.563 | 0.917 | 0.739 | 0.321 | |
| Debt To Equity Ratio | -1.947 | -5.826 | -1.956 | -6.954 | 1.107 | |
| Debt To Capital Ratio | 2.056 | 1.207 | 2.046 | 1.168 | 0.525 | |
| Long Term Debt To Capital Ratio | 2.445 | 1.265 | 2.748 | 1.215 | 0.369 | |
| Financial Leverage Ratio | -2.160 | -10.354 | -2.134 | -9.405 | 3.450 | |
| Working Capital Turnover Ratio | 0.107 | 0.025 | 0.012 | 0.161 | 0.155 | |
| Operating Cash Flow Ratio | -2.519 | -2.203 | -4.035 | -3.540 | -1.983 | |
| Operating Cash Flow Sales Ratio | -5.793 | -21.430 | -55.024 | -3.167 | -2.024 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.049 | 1.010 | 1.003 | 1.038 | 1.343 | |
| Debt Service Coverage Ratio | -5.342 | -5.034 | -6.741 | -6.370 | -6.263 | |
| Interest Coverage Ratio | -5.895 | -6.199 | -8.605 | -6.338 | -6.352 | |
| Short Term Operating Cash Flow Coverage Ratio | -12.385 | -34.365 | -41.104 | -312.647 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.397 | -0.502 | -0.548 | -0.399 | -0.528 | |
| Capital Expenditure Coverage Ratio | -20.559 | -101.354 | -292.608 | -26.424 | -2.916 | |
| Dividend Paid And Capex Coverage Ratio | -20.559 | -101.354 | -292.608 | -26.424 | -2.916 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.342 | -12.080 | -19.054 | -14.460 | -19.933 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 88.5% | ▲1825.7% | ▲1331.4% |
| Ebit Margin | -891.6% | ▲1831.2% | ▲1200.1% |
| Ebitda Margin | -880.1% | ▲1791.1% | ▲1165.5% |
| Operating Profit Margin | -695.4% | ▲2207.3% | ▲1463.6% |
| Pretax Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Continuous Operations Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Net Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Bottom Line Profit Margin | -891.6% | ▲2299.5% | ▲1466.1% |
| Current Ratio | 4.529 | ▼-1.637 | ▼-2.204 |
| Quick Ratio | 4.529 | ▼-1.637 | ▼-2.204 |
| Solvency Ratio | -0.372 | ▲0.006 | ▲0.003 |
| Cash Ratio | 0.605 | ▲0.077 | ▼-0.310 |
| Price To Earnings Ratio | -9.716 | ▼-0.773 | ▲2.452 |
| Price To Earnings Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Forward Price To Earnings Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Price To Earnings Diluted Ratio | -9.716 | ▼-0.773 | ▲2.452 |
| Price To Earnings Diluted Growth Ratio | -0.399 | ▼-2.965 | ▼-0.598 |
| Price To Book Ratio | -11.562 | ▲27.350 | ▲7.460 |
| Price To Sales Ratio | 86.624 | ▼-198.506 | ▼-220.426 |
| Price To Free Cash Flow Ratio | -14.260 | ▼-1.084 | ▲1.414 |
| Price To Operating Cash Flow Ratio | -14.953 | ▼-1.648 | ▲2.255 |
| Debt To Assets Ratio | 0.901 | ▲0.339 | ▲0.213 |
| Debt To Equity Ratio | -1.947 | ▲3.879 | ▲1.168 |
| Debt To Capital Ratio | 2.056 | ▲0.849 | ▲0.656 |
| Long Term Debt To Capital Ratio | 2.445 | ▲1.180 | ▲0.837 |
| Financial Leverage Ratio | -2.160 | ▲8.195 | ▲1.961 |
| Working Capital Turnover Ratio | 0.107 | ▲0.082 | ▲0.015 |
| Operating Cash Flow Ratio | -2.519 | ▼-0.316 | ▲0.337 |
| Operating Cash Flow Sales Ratio | -5.793 | ▲15.637 | ▲11.694 |
| Free Cash Flow Operating Cash Flow Ratio | 1.049 | ▲0.039 | ▼-0.040 |
| Debt Service Coverage Ratio | -5.342 | ▼-0.308 | ▲0.608 |
| Interest Coverage Ratio | -5.895 | ▲0.304 | ▲0.783 |
| Short Term Operating Cash Flow Coverage Ratio | -12.385 | ▲21.981 | ▲67.716 |
| Operating Cash Flow Coverage Ratio | -0.397 | ▲0.105 | ▲0.078 |
| Capital Expenditure Coverage Ratio | -20.559 | ▲80.795 | ▲68.213 |
| Dividend Paid And Capex Coverage Ratio | -20.559 | ▲80.795 | ▲68.213 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.342 | ▲0.738 | ▲4.032 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.63B | $5.27B | $8.06B | $4.12B | $3.50B | |
| Enterprise value | $8.79B | $5.96B | $8.70B | $4.80B | $3.66B | |
| EV / Sales | 99.82x | 322.69x | 1155.58x | 50.75x | 51.99x | |
| EV / Op. cash flow | -17.23x | -15.06x | -21.00x | -16.03x | -25.69x | |
| EV / Free cash flow | -16.43x | -14.91x | -20.93x | -15.44x | -19.13x | |
| EV / EBITDA | -11.34x | -12.08x | -19.05x | -14.46x | -19.93x | |
| Net debt / EBITDA | -1.50x | -1.41x | -1.41x | -2.06x | -0.86x | |
| Current ratio | 4.53x | 6.17x | 6.12x | 9.40x | 7.45x | |
| Income quality | 0.65x | 0.67x | 0.79x | 0.77x | 0.66x | |
| Graham net-net | -$10 | -$4 | -$6 | -$4 | -$1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 117.2% | 112.3% | 115.1% | 115.8% | |
| Working capital | $714.5M | $928.3M | $525.4M | $710.6M | $463.8M | |
| Invested capital | $869.7M | $1.07B | $673.1M | $873.8M | $610.2M | |
| Return on assets | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% | |
| Operating ROA | -43.3% | -48.2% | -54.0% | -34.9% | -27.1% | |
| Return on tangible assets | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% | |
| Return on equity | 119.0% | 435.5% | 136.2% | 360.5% | -88.3% | |
| Return on invested capital | -47.7% | -42.8% | -66.2% | -34.3% | -23.8% | |
| Return on capital employed | -50.1% | -43.9% | -68.8% | -34.9% | -24.2% | |
| Earnings yield | -10.3% | -11.2% | -6.5% | -9.5% | -6.1% | |
| Free cash flow yield | -7.0% | -7.6% | -5.2% | -7.6% | -5.5% | |
| Capex / Op. cash flow | -4.9% | -1.0% | -0.3% | -3.8% | -34.3% | |
| Capex / Depreciation | 245.0% | 41.0% | 11.9% | 195.0% | 2147.3% | |
| Capex / Sales | 28.2% | 21.1% | 18.8% | 12.0% | 69.4% | |
| SG&A / Sales | 322.9% | 1165.5% | 2305.6% | 188.2% | 137.4% | |
| R&D / Sales | 461.0% | 1837.2% | 4384.1% | 254.6% | 227.1% | |
| Stock comp / Sales | 127.5% | 529.6% | 957.0% | 50.6% | 38.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 74d | 329d | 62d | 1d | 269d | |
| Days payables outstanding | 805d | 22d | 24d | 39d | 48d | |
| Operating cycle | 74d | 329d | 62d | 1d | 269d | |
| Cash conversion cycle | -732d | 307d | 38d | -38d | 220d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years